Circulating Tumor Cells in Desmoid Tumors: New Perspectives.

Autor:	Braun AC; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Campos FAB; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Abdallah EA; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Ruano APC; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Medina TDS; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil., Tariki MS; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Pinto FFE; Department of Orthopedics, A. C. Camargo Cancer Center, São Paulo, Brazil., de Mello CAL; Department of Clinical Oncology, A. C. Camargo Cancer Center, São Paulo, Brazil., Chinen LTD; International Center for Research, A.C. Camargo Cancer Center, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Sep 14; Vol. 11, pp. 622626. Date of Electronic Publication: 2021 Sep 14 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.622626
Abstrakt:	Introduction: Desmoid tumor (DT) is a rare neoplasm with high local recurrence rates, composed of fibroblastic cells that are characterized by the expression of key molecules, including the intermediate filament vimentin, cyclooxygenase-2 (COX-2), and nuclear β-catenin, and lack of epithelial markers. Circulating tumor cells (CTCs) isolated from the peripheral blood of patients with sarcomas and other neoplasms can be used as early biomarkers of tumor invasion and dissemination. Moreover, CTCs can also re-colonize their tumors of origin through a process of "tumor self-seeding." Objectives: We aimed to identify CTCs in the peripheral blood of patients with DT and evaluate their expression of β-catenin, transforming growth factor receptor I (TGF-βRI), COX-2, and vimentin proteins. Material and Methods: We conducted a prospective study of patients with initial diagnosis or relapsed DT with measurable disease. Blood samples from each patient were processed and filtered by ISET ® (Rarecells, France) for CTC isolation and quantification. The CTC expression of β-catenin, COX-2, TGF-βRI, and vimentin was analyzed by immunocytochemistry (ICC). Results: A total of 18 patients were included, and all had detectable CTCs. We found a concordance of β-catenin expression in both CTCs and primary tumors in 42.8% (6/14) of cases by using ICC and immunohistochemistry, respectively. Conclusions: Our study identified a high prevalence of CTCs in DT patients. Concordance of β-catenin expression between primary tumor and CTCs brings new perspectives to assess the dynamics of CTCs in the blood compartment, opening new avenues for studying the biology and behavior of DT. In addition, these results open the possibility of using CTCs to predict DT dynamics at the time of disease progression and treatment. Further studies with larger sample sizes are needed to validate our findings. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Braun, Campos, Abdallah, Ruano, Medina, Tariki, Pinto, de Mello and Chinen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu